PRA Health Sciences (PRAH) Tops Q1 EPS by 2c; Boosts FY16 EPS Outlook

PRA Health Sciences (NASDAQ: PRAH) reported Q1 EPS of $0.55, $0.02 better than the analyst estimate of $0.53. Revenue for the quarter came in at $372.3 million versus the consensus estimate of $372.21 million.

GUIDANCE:

PRA Health Sciences sees FY2016 EPS of $2.41-$2.48, versus prior guidance of $2.32-$2.42 and the consensus of $2.38.

For earnings history and earnings-related data on PRA Health Sciences (PRAH) click here.

You May Also Be Interested In

• DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
• Bernstein SocGen Group Upgrades Whitbread PLC. (WTB:LN) (WTBCF) to Market Perform
• HSBC Upgrades Blue Star Limited (BLSTR:IN) to Buy